# Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer

Source: https://onco.cc/trials/nct05065957/  
OnCo record `nct05065957` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial testing D07001 in biliary tract cancer, now recruiting.

## Summary

Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer is a phase 2/3 interventional study registered as NCT05065957, led by InnoPharmax, and recruiting on the registry. Official title: Open-Label, Multicenter, Phase II/III Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer After Gemcitabine and Cisplatin-Based Treatment Failure. Planned enrolment is 180 participants (estimated). The study started in 2022-03-29 and primary completion is expected in 2026-07. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT05065957
- Phase: 2/3
- Setting: Open-Label, Multicenter, Phase II/III Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer After Gemcitabine and Cisplatin-Based Treatment Failure
- Sponsor: InnoPharmax
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT05065957: https://clinicaltrials.gov/study/NCT05065957

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/)
- drugs: [D07001](https://onco.cc/drugs/d07001/)
- companies: [InnoPharmax](https://onco.cc/companies/innopharmax/)

---
JSON: https://onco.cc/api/v1/entities/nct05065957.json